Compare TNC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | CGEM |
|---|---|---|
| Founded | 1870 | 2016 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1994 | 2020 |
| Metric | TNC | CGEM |
|---|---|---|
| Price | $67.59 | $20.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $79.00 | $30.13 |
| AVG Volume (30 Days) | 156.6K | ★ 750.3K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,137,600,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $4.95 | $5.20 |
| P/E Ratio | $148.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.18 | $5.68 |
| 52 Week High | $91.93 | $23.19 |
| Indicator | TNC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 49.46 |
| Support Level | $64.88 | $11.87 |
| Resistance Level | $88.96 | $23.19 |
| Average True Range (ATR) | 2.20 | 0.96 |
| MACD | 0.09 | -0.26 |
| Stochastic Oscillator | 9.62 | 51.40 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.